Title:
Towards a new integral (physiological / metabolic / biochemical / molecular) paradigm for the generation of anti-cancer therapeutics: breaking through a cancer cell’s defense by targeting hypoxia and acidosis.
Agreement Value:
$25,000.00
Agreement Date:
May 20, 2020 - Mar 31, 2022
Description:
The team will perform studies to test the potential therapeutic efficacy of a new antibody (Ab)-based drug, called a single domain Ab (sdAb), that specifically blocks the activity of a protein called carbonic anhydrase IX (CAIX). CAIX is expressed by cancer cells in environments with low levels of oxygen (hypoxia) and is used by cancer cells to regulate proper metabolism, allowing for survival in hypoxia. Cancer cells will be cultured and tested whether the sdAbs are able to block the activity of CAIX produced on these cells. The team willl carry out experiments to determine whether sdAbs inhibit the growth of cultured cancer cells. The team will also investigate whether sdAbs that carry a toxin will kill cancer cells. Based on these experiments, the team willl conduct studies to determine whether the sdAbs, with or without toxins, are able to block the growth of human tumors in mice. These initial studies are a first step in developing CAIX-specific sdAbs for use as cancer therapies.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators.
Location:
Vancouver, British Columbia, CA V5Z 1L3
Reference Number:
172-2020-2021-Q4-946579
Report Type:
Grants and Contributions
Recipient Business Number:
863530135
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 365 days.
Amendment Date
Jan 26, 2021
Recipient's Legal Name:
BC Cancer Agency
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Collaborative Science, Technology and Innovation Program – Ideation Fund
Program Purpose:
The Ideation Fund is intended to encourage, test and validate transformative research ideas generated by teams of NRC scientific personnel and external collaborators with complementary capabilities, acting as a demonstration phase for a continually-evolving suite of research and development (R&D) deliverables at the NRC. The fund supports exploratory research through two mechanisms: the New Beginnings Initiative and the Small Teams Initiative.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences